EVOTEC SE

Evotec SE climbs 5 % to €2.88, outpacing a muted tech market while short sellers linger—learn how its drug‑discovery focus and technical indicators shape the outlook.

Evotec SE shares rise 3.5% on March 21, 2026, amid steady market standing and a 200‑day SMA at €4.51. Discover how the pharma firm’s drug‑discovery focus fuels investor confidence.